Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Common Equity (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Common Equity for 6 consecutive years, with $84.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 47.03% year-over-year to $84.5 million, compared with a TTM value of $84.5 million through Sep 2025, down 47.03%, and an annual FY2024 reading of $130.0 million, down 30.46% over the prior year.
  • Common Equity was $84.5 million for Q3 2025 at Barinthus Biotherapeutics, down from $102.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $254.8 million in Q2 2022 and bottomed at -$52.8 million in Q1 2021.
  • Average Common Equity over 5 years is $181.1 million, with a median of $195.6 million recorded in 2023.
  • Peak annual rise in Common Equity hit 954.6% in 2021, while the deepest fall reached 104.32% in 2021.
  • Year by year, Common Equity stood at $252.6 million in 2021, then fell by 3.71% to $243.2 million in 2022, then dropped by 23.11% to $187.0 million in 2023, then plummeted by 30.46% to $130.0 million in 2024, then plummeted by 35.04% to $84.5 million in 2025.
  • Business Quant data shows Common Equity for BRNS at $84.5 million in Q3 2025, $102.5 million in Q2 2025, and $115.6 million in Q1 2025.